| Z04690 | |
|
|
|
| ¥80,213.00 | |
|
|
|
|
|
|
| Ask us a question | |
| Species | Canine | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its ability to inhibit rhBMP4induced alkaline phosphatase production by ATDC5 cells. The ED50 for this effect is typically 0.5 2.5 μg/mL in the presence of 50 ng/mL of recombinant human BMP4. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 40.94 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 50-65 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | The type IA bone morphogenetic protein receptor (Bmpr1a), encoded by 11 exons and spanning about 40 kb on chromosome 14 in mice and chromosome 10 in human (Derynck & Feng, 1997; Mishina, Hanks, Miura, Tallquist, & Behringer, 2002), is an essential receptor for BMP signaling. |
| Synonyms | BMPR1A; ALK-3; ALK3; ALK 3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
